Development of interventions for the secondary prevention of Alzheimer’s dementia: the European Prevention of Alzheimer’s Dementia (EPAD) project

Craig W Ritchie, José Luis Molinuevo, Luc Truyen, Andrew Satlin, Serge Van der Geyten, Simon Lovestone, on behalf of the European Prevention of Alzheimer’s Dementia (EPAD) Consortium

Alzheimer’s dementia affects more than 40 million people worldwide with substantial increases in prevalence anticipated. Interventions that either modify risk or reduce the development of early disease could delay the onset of dementia or reduce the rate of cognitive and functional decline. The European Prevention of Alzheimer’s Dementia (EPAD) is a public–private consortium, funded by the Innovative Medicines Initiative, designed to increase the likelihood of successful development of new treatments for the secondary prevention of Alzheimer’s dementia. EPAD will help with testing of different agents in this predementia population through four components: improvement of access to existing cohorts and registries, development of the EPAD Registry of approximately 24 000 people who might be at increased risk of developing Alzheimer’s dementia, establishment of the EPAD Longitudinal Cohort Study of 6000 people at any one time, and establishment of an adaptive, proof-of-concept trial including 1500 participants at any given time. The need for EPAD and its key design elements are described, and we discuss EPAD in relation to similar projects in progress. These parallel efforts reflect the need for a coordinated, worldwide battle against dementia, in which EPAD will play a crucial role.

Lancet Psychiatry 2015

Published Online
December 9, 2015
http://dx.doi.org/10.1016/S2215-0366(15)00454-X